Determination criteria of clinical effect: If hemato-
ma was removed thoroughly and there were no ob- vious clinical symptoms and vital signs, then treat- ment was considered to be statistically effective; if hematoma was removed thoroughly and clinical symptoms and vital signs were relieved, then treat- ment was considered to be effective; if hematoma was not removed thoroughly and clinical symp- toms and vital signs had no obvious improvement or even aggravated, then treatment was thought to be ineffective.
Accordingly, we conducted dose-response analyses for a) lung cancer (ICD-9 162); b) upper aerodigestive tract cancers encompassing the naso-oropharyngeal regions, esophagus, and stomach (ICD-9 140-151); c) hemato-
and lymphopoietic cancers (ICD-9 200-208, excluding chronic lymphatic leukemias); d) urinary-tract cancers (ICD-9 188-189); and e) prostate cancer (ICD-9 185).
Clinical findings, hemato-
biochemical analysis, identification of H.